Lumos Health Advisory, Asia’s premier healthcare speed-scaling programme, has announced the opening of applications for its second cohort, inviting early-stage healthcare startups from across Asia and beyond to apply before the June 25, 2026 deadline. The programme is designed to support founders building innovative solutions in healthtech and medtech by providing access to clinical infrastructure, regulatory expertise, market opportunities, and investor networks.
Founded by Anjali Ajaikumar Rossi and Prasad Vanga, Lumos Health was created to address a critical challenge faced by healthcare startups: scaling beyond the prototype stage. While access to capital remains important, the founders believe that successful healthcare innovation also requires clinical validation, strategic guidance, and ecosystem support to navigate the complex healthcare landscape.
Bridging Innovation and Healthcare Ecosystems
Lumos Health operates through a strategic partnership between Anjali Ajaikumar, Director of HCG, and Anthill Ventures, a global venture capital platform managing a $100 million fund with strong business and investor networks across India, the United States, and Singapore.
This collaboration offers participating startups access to a unique combination of clinical infrastructure and commercial growth opportunities. Through Lumos Health’s extensive hospital and healthcare partner network, startups can gain support for clinical trials, real-world product validation, and market deployment—significantly reducing the time required to bring healthcare innovations to market.
Comprehensive Support for Healthcare Founders
Selected startups will receive a wide range of support services designed specifically for the healthcare sector, including:
- Regulatory guidance and compliance support
- Clinical validation and trial assistance
- Market access opportunities
- Fundraising and investor introductions
- One-on-one mentorship from healthcare experts
- Cohort-based learning sessions
- Infrastructure and ecosystem support
The programme is particularly focused on startups working in preventive health and longevity, oncology innovation, fertility and women’s health, genetics and genomics, diagnostics, and medtech.
Additionally, Lumos Health encourages applications from companies developing solutions based on artificial intelligence, predictive analytics, IoT-enabled remote monitoring, self-testing technologies, image-based pathology, blockchain applications, and healthcare big data.
Driving Meaningful Healthcare Innovation
Speaking about the programme, Anjali Ajaikumar Rossi emphasized that healthcare innovation requires more than technological advancement.
“A successful healthcare startup today cannot solely depend upon technology as a differentiator. Healthcare innovation requires constant access to clinicians, patients, and regulatory frameworks, as well as the right ecosystem and market pathways to move from pilot testing to actual use. Through bridging healthcare expertise, clinical infrastructure, and investor networks, we help founders move faster with confidence,” she said.
She added that Lumos Health aims to foster stronger collaboration between healthcare providers, innovators, investors, and industry stakeholders to translate breakthrough ideas into meaningful patient outcomes.
Success Stories from the First Cohort
The inaugural Lumos Health cohort demonstrated the programme’s ability to create meaningful partnerships between startups and the broader healthcare ecosystem. Alumni companies such as ErlySign, RayIoT, KroniKare, AyuRhythm, and Deep Holistics leveraged Lumos Health’s clinical networks and Anthill Ventures’ investor ecosystem to accelerate their growth.
Reflecting on the programme’s impact, Shubhendra Singh Thakur, CEO and Founder of Erly Sign, said the support from Lumos Health and HCG Group of Hospitals played a crucial role in helping the company validate and refine its healthcare solution within a real-world clinical environment.
Supporting Startups at a Critical Growth Stage
Lumos Health focuses on a particularly important phase in a startup’s journey—the transition from seed stage to early expansion. This is often the period when founders require the most practical support to validate their products, secure partnerships, and prepare for scaling.
To date, the programme has reviewed more than 500 startups, received over 350 applications, and selected eight startups for its portfolio, demonstrating a highly curated and focused approach to supporting healthcare innovation.
As healthcare systems increasingly embrace digital transformation, programmes like Lumos Health are playing a vital role in helping emerging startups navigate the industry’s complexities while accelerating the adoption of impactful technologies that can improve patient outcomes across the region.
By:Arushi Agarwal
